PL BioScience Strengthens Management Team with Appointment of Oliver Dick as Chief Technology Officer
|
EQS-News: PL BioScience GmbH
/ Key word(s): Personnel
PL BioScience Strengthens Management Team with Appointment of Oliver Dick as Chief Technology Officer Oliver Dick, PhD, brings 30 years of expertise in building and leading operations departments in life science, diagnostic and biopharmaceutical companies Aachen, Germany, 11 June 2025 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the strengthening of its management team with the appointment of Oliver Dick, PhD, as Chief Technology Officer, a strategic position as the company scales up to meet growing global demand for its animal-free cell culture solutions. Oliver Dick is an experienced operations executive with over 30 years of experience in project and line management across supply chain management (SCM), production, quality control (QC), quality assurance (QA), logistics, engineering and technology transfer. His expertise lies in developing and leading operational strategies along the entire supply chain within life science, diagnostic, and biopharmaceutical organizations. “Oliver has an extensive track record in operational excellence and brings a strategic vision as well as hands-on leadership in life sciences and biopharma manufacturing to our team. With global demand for animal-free cell culture supplements increasing, we are advancing our international growth strategy and are delighted to have him as we enter into this exciting phase,” said Dr. Hatim Hemeda, CEO of PL BioScience. “I am very excited to join PL BioScience as CTO at a time of such dynamic growth and opportunity,” said Dr. Oliver Dick. “The company has built a strong reputation for product innovation and quality in Human Platelet Lysate and is in an excellent position to shape the market globally. I look forward to working with the highly qualified team to ensure PL BioScience’s commercial success.” Prior to joining PL BioScience, Oliver Dick held senior leadership roles including Chief Operating Officer and Vice President of Operations at both global biotech companies such as Resolve BioSciences, Rentschler, and Miltenyi Biotec, as well as international corporations including Fresenius and Qiagen. Throughout his career, he has consistently driven cross-functional initiatives aimed at process optimization, cost reduction, and digital transformation across the supply chain. He holds an engineering degree and a PhD in biochemical engineering from the Technical University of Dortmund.
About Human Platelet Lysate: HPL is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. Natural HPL is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable yet limited alternative to animal-derived cell culture supplements. A next-generation, fully artificial alternative made from lab-grown platelets has been developed by PL BioScience to secure the future supply. In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices. ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.
About PL BioScience: PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL allowing for a fully lab-made, scalable supply of HPL in the future. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/
Contact:
Media contact:
11.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | PL BioScience GmbH |
| Dennewartstr. 25-27 | |
| 52068 Aachen | |
| Germany | |
| E-mail: | info@pl-bioscience.com |
| Internet: | www.pl-bioscience.com |
| EQS News ID: | 2153340 |
| End of News | EQS News Service |
|
|
2153340 11.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.